TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A male or female child of between 5 months and 17 months of age at the time of first vaccination.~* Written or oral, signed or thumb-printed and witnessed informed consent obtained from the parent(s)/guardian(s) of the child..~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.~Exclusion Criteria:~* Acute disease at the time of enrolment.~* Serious acute or chronic illness determined by clinical or physical examination and laboratory screening tests.~* Laboratory screening tests for haemoglobin, total white cell count, platelets, ALT and creatinine out of acceptable limits.~* Planned administration/administration of a vaccine not foreseen by the study within 30 days of the first dose of vaccine(s) with the exception of tetanus toxoid or scheduled diphtheria, pertussis or measles vaccine.~* Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Administration of immunoglobulins, blood transfusions or other blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the first vaccine dose~* Previous participation in any other malaria vaccine trial.~* Simultaneous participation in any other clinical trial.~* Same sex twin.~* History of allergic reactions (significant IgE-mediated events) or anaphylaxis to previous immunizations.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trial.

- Gender: ALL
- Minimum Age: 5 Months
- Maximum Age: 17 Months
- Healthy Volunteers: t

Study Arms:
- GSK257049 Group (Type: EXPERIMENTAL): Male or female subjects between 5 and 17 months of age at the time of first vaccination received 3 doses of GSK257049 vaccine administered intramuscularly in the left deltoid muscle at Days 0, 30 and 60.
- Rabipur Group (Type: ACTIVE_COMPARATOR): Male or female subjects between 5 and 17 months of age at the time of first vaccination received 3 doses of Rabipur vaccine administered intramuscularly in the left deltoid muscle at Days 0, 30 and 60.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Physical Activity Program in End-state Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 40 to 70.~* Cirrhosis, any cause, defined as:~  * Biopsy-proven.~ * Two or more of the following: albumin \<3.5 g/dL, International Normalized Ration (INR) \>1.3, radiologic or endoscopic evidence of portal hypertension.~* Creatinine \<2.0 mg/dL.~* Physiologic Model for End Stage Liver Disease (MELD) ≥10.~* Decompensated cirrhosis with active or history of variceal bleeding, ascites, hepatic encephalopathy, or jaundice.~* Potential transplant candidate as per UAMS criteria~Exclusion Criteria:~* Large gastric or esophageal varices with contraindication to use beta-blockers.~* Persistent hepatic encephalopathy grades 2-4.~* Prior diagnosis of hepatocellular carcinoma, or hepatic hydrothorax (with prior repeated thoracocentesis).~* Cirrhotic cardiomyopathy or congestive heart failure, pulmonary vascular complications, known active coronary artery disease, syncope, and cardiac dysrhythmias.~* Physical impediment to perform a cardiorespiratory fitness test.~* Use of implantable defibrillator or a pacemaker.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Active (physical training program) (Type: EXPERIMENTAL): physical activity + behavioral therapy + nutritional intervention
- Control (Type: ACTIVE_COMPARATOR): nutritional intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who had received a primary or secondary kidney transplant~* Patients who were willing and from whom written informed consent was obtained~* kidney allograft with a cold ischemia time (CIT) \< 30 hours~* negative pregnancy test prior to study enrollment~Exclusion Criteria:~--Multi-organ recipients~* former Graft loss due to immunological reasons~* Patients who received a kidney from a non-heart beating donor~* A-B-0 incompatible transplants~* a current Panel Reactive Antibody (PRA) level of \> 20%~* existing antibodies against the HLA-type of the receiving transplant~* a known hypersensitivity/contraindication to any of the immunosuppressants~* Use of other investigational drugs~* Patients with thrombocytopenia (platelets \< 100,000/mm³), with an absolute neutrophil count of \< 2,000/mm³ or leucopenia (leucocytes \< 3,000/mm³), or hemoglobin \< 8 g/dL~* significant mental illness~* history of malignancy during the last five years~* HIV positive~* uncontrolled hypercholesterolemia or hypertriglyceridemia~* drug or alcohol abuse~* pregnant or breast feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAC+MPA (Type: ACTIVE_COMPARATOR): None
- TAC+Certican (Type: EXPERIMENTAL): None
- CycA+Certican (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage I-IIIa breast cancer~* Postmenopausal or recently postmenopausal~* Recent surgery for breast cancer~* Estrogen Receptor positive and/or progesterone receptor positive hormone receptor status~* No prior treatment with letrozole~Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Metastatic disease~* Invasive bilateral disease~* Clinical or radiological evidence of existing fracture in spine or hip~* Prior treatment with IV bisphosphonates in the past 12 months~* Current treatment with oral bisphosphonates ( must be discontinued within 3 weeks of baseline evaluation)~* Use of Tibolone within 6 months~* Prior use of parathyroid hormone for more than 1 week~* Previous or concomitant malignancy~* Abnormal renal function~* History of disease effecting bone metabolism~Other protocol-defined exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Upfront Zoledronic Acid (Type: EXPERIMENTAL): Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.
- Delayed Zoledronic Acid (Type: EXPERIMENTAL): Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score \<= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Patients with a prior MI within the previous 2 weeks to 12 months.~2. On DAPT with low-dose aspirin (81mg od) and either prasugrel (10mg od) or ticagrelor (90mg bid) as per standard-of-care for at least 2 weeks.~3. Free from bleeding and ischemic events after the index MI event.~4. Age between 18 and 75 years old.~Exclusion criteria:~1. History of stroke, transient ischemic attack, or intracranial hemorrhage.~2. Active pathological bleeding, history of bleeding events or increased risk of bleeding.~3. Known severe hepatic impairment.~4. Age \>75 years.~5. Body weight \<60 Kg.~6. Use of strong Cytochrome P450 3A inhibitors (e.g., ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin and conivaptan) or inducers (e.g., rifampin, carbamazepine, St. John's Wort and phenytoin).~7. On treatment with any oral anticoagulant (vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxaban).~8. On treatment with any antiplatelet agent other than aspirin, prasugrel and ticagrelor in the past 14 days.~9. Creatinine clearance \<30 mL/minute.~10. Platelet count \<80x106/mL~11. Hemoglobin \<10g/dL~12. Hemodynamic instability~13. Pregnant females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DAPT plus vorapaxar (Type: EXPERIMENTAL): Aspirin plus prasugrel or ticagrelor plus vorapaxar 2.5mg od
- Prasugrel/ticagrelor plus vorapaxar (Type: EXPERIMENTAL): Prasugrel or ticagrelor plus vorapaxar 2.5mg od
- DAPT (Type: ACTIVE_COMPARATOR): Aspirin in addition to prasugrel or ticagrelor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for first cytotoxic chemotherapy cycle, regardless of the line of treatment, because of hematologic malignancies at intermediate or high risk of TLS (according to the TLS risk stratification, Cairo M et al, British Journal of Haematology, 2010)candidate to Allopurinol treatment or have no access to Rasburicase~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3~* Life expectancy \> 1 month~Exclusion Criteria:~* Patients known to be hypersensitive to Febuxostat or Allopurinol or to any of the components of the formulations~* Patients with sUA levels ≥ 10 mg/dL at randomization~* Patients receiving Febuxostat, Allopurinol or any other urate lowering therapy (e.g. Rasburicase, probenecid) within 30 days prior to randomization~* Patients with severe renal and/or hepatic insufficiency~* Patients with diagnosis of LTLS or CTLS at randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Febuxostat (Type: EXPERIMENTAL): Febuxostat for 7-9 days
- Allopurinol (Type: ACTIVE_COMPARATOR): Allopurinol for 7-9 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, 35-65 years of age~* Hepatic steatosis assessed by magnetic resonance spectroscopy (MRS) with liver fat \>5.56% at screening~* Body mass index (BMI) \>27 kg/m2 at screening~* Insulin resistance assessed by homeostatic model assessment-insulin resistance (HOMA-IR) \> 2.5 at screening~* Agreement to maintain prior diet and exercise habits during the full course of study~Exclusion Criteria:~* History of diabetes mellitus based on World Health Organization (WHO) criteria~* Known polycystic ovary syndrome~* Other liver disease e.g. chronic viral hepatitis, alcoholic liver disease, hemachromatosis, cirrhosis~* Known autoimmune disease or chronic inflammatory disease~* Myocardial infarction or stroke within 6 months prior to screening~* Patients taking any anti-diabetic and/or weight-lowering medication currently or within the previous 3 months before screening

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of a solid tumor that is not responsive to standard therapies or for which there is no approved or curative therapy.~* Subjects must have BRAF V600E or K mutant positive tumors.~* Women with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 4 weeks after the last dose of study medication.~* Men with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 16 weeks after the last dose of study medication.~* Must have adequate organ function.~* Must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.~Exclusion Criteria:~* Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy or surgery).~* Use of an investigational anti-cancer drug within 28 days preceding the first dose of GSK2118436.~* A history of other malignancy. Subjects who have been disease-free for 5 years or subjects with a history of complete resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.~* History of Human Immunodeficiency Virus (HIV) infection.~* Certain cardiac abnormalities.~* Pregnant or lactating female.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Escalation Part (Type: EXPERIMENTAL): Dose escalation will be conducted to assess safety, tolerability, single and repeat dose PK profile and preliminary efficacy of GSK2118436 . The dose may be escalated to the overseas recommended phase III dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is at least 18 years of age~* Level of severity of bilateral nasolabial fold wrinkles meeting severity criteria as per protocol~* Level of subject dissatisfaction with both nasolabial fold wrinkles as per protocol~* Ability to comply with the study requirements~* Negative pregnancy test (Females)~* Healthy post-auricular skin for biopsy~Exclusion Criteria:~* Excessive dermatochalasis of the treatment area~* Inability to lessen the nasolabial fold wrinkles by physically spreading the area apart~* Total area to be treated exceeds 20 cm in length~* Physical attributes which may prevent assessment or treatment as judged by the evaluator~* Use of an investigational product/procedure within 30 days prior to enrollment or plans for use during the study~* Previous treatment with the sponsor's product~* History of active autoimmune disease or organ transplantation~* Diagnosis of cancer, unless successfully treated or in remission (basal cell carcinoma is excluded)~* Active or chronic skin disease~* Known genetic disorders affecting fibroblasts or collagen~* Active systemic infection~* Requires chronic antibiotic or steroidal therapy~* Use of certain commercial products/procedures to the treatment area prior to study enrollment or plans for use during the study~* Use of systemic agents that increase bleeding or clotting, or disorders equated with these effects~* Known allergic reactions to agents used in preparation of treatment~* Excessive exposure to sun without adequate sun protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~For the idiopathic pulmonary fibrosis (IPF) Cohort~* Diagnosis of IPF within 7 years of screening~* Female and males ≥ 40 years of age~For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort~* Evidence of progressive ILD within the 24 months before screening~* Female and male ≥ 21 years of age.~Exclusion Criteria:~* Women of childbearing potential (WOCBP)~* Active Smokers~* Current malignancy or previous malignancy up to 5 years prior to screening~* History of allergy to BMS-986278 or related compounds~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IPF Dose 1 + Post Treatment Follow-up or OTE (Type: EXPERIMENTAL): IPF (Idiopathic Pulmonary Fibrosis) OTE (Optional Treatment Extension)
- IPF Dose 2 + Post Treatment Follow-up or OTE (Type: EXPERIMENTAL): None
- IPF Placebo + Post Treatment Follow-up or OTE (Type: PLACEBO_COMPARATOR): None
- PF-ILD Dose 1 + Post Treatment Follow-up or OTE (Type: EXPERIMENTAL): PF-ILD (Progressive Fibrotic Interstitial Lung Disease)
- PF-ILD Dose 2 + Post Treatment Follow-up or OTE (Type: EXPERIMENTAL): None
- PF-ILD Placebo + Post Treatment Follow-up or OTE (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Spinal Induced Shivering During CS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* pregnant women at term,~* ASA status I or II (American Society of Anesthesiologists) physical status class I-II,~* low-risk cesarean section,~* Scheduled for the spinal anesthesia~Exclusion Criteria:~* Pregnant women in labor~* Patients who have the body temperature over 37.3 or less than 37 celsius degree~* Known allergies to the study drugs~* Contraindication to spinal anesthesia

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Granisetron 1 (Type: ACTIVE_COMPARATOR): Intravenous granisetron 1 mg
- Granisetron 0.7 (Type: ACTIVE_COMPARATOR): Intravenous granisetron 0.7 mg
- Placebo (Type: PLACEBO_COMPARATOR): intravenous 0.9% Sodium chloride (2 ml)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete